NASDAQ$DH

Definitive Healthcare Corp · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Definitive Healthcare reported financial results, with Q4 revenue increasing by 9% year-over-year.

Definitive Healthcare reported Q4 2023 financial results, highlighting a 9% year-over-year increase in revenue to $65.9 million. The company's net loss was $13.4 million, while adjusted EBITDA reached $19.8 million, representing 30% of revenue.

  • Revenue increased by 9% year-over-year, reaching $65.9 million.
  • Net loss was $13.4 million, representing (20)% of revenue.
  • Adjusted Net Income was $10.6 million, compared to $10.3 million in Q4 2022.
  • Adjusted EBITDA was $19.8 million, or 30% of revenue.

Headline financials

Total Revenue

$65.9M

Previous: $60.6M+8.8%
EPS (adj)

$0.07

Previous: $0.07+0.0%
Adjusted Net Income

$10.6M

No prior period
Adjusted EBITDA Margin

30.0%

No prior period
Adjusted Gross Profit

$55.8M

No prior period
Adjusted Gross Margin

85.0%

No prior period
Adjusted Operating Income

$18.3M

No prior period
Cash Flow from Operations

$4.71M

No prior period
Unlevered Free Cash Flow

$11.1M

No prior period
Capital Expenditures

-$594K

Previous: $4.87M-112.2%
Net Income

-$13.4M

Previous: $6.7M-299.4%
Operating Income

-$10.1M

Previous: -$9.63M-4.6%
Gross Profit

$43.5M

Previous: $50.8M-14.4%
R&D Expense

$11.6M

No prior period
Stock-Based Comp

$13.3M

Previous: $11.4M+16.0%

Revenue & EPS history

Definitive Healthcare · Revenue · Quarterly

$65.9M

Q4 2023+8.8%vs Q4 2022
Beat estimate in 12 of 14 quarters(86%)
ActualEstimate

Forward guidance

Definitive Healthcare issued financial guidance including the effect of the acquisition of the Carevoyance product suite.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-3.2%

Avg return

Earnings day

-5.7%

Avg return

5 days after

-5.8%

Avg return

30 days after

39%

7 / 18 earnings

Positive

+31.7%

Q1 2025

Best reaction

-34.3%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.2%-2.0%-5.2%
Q4 2025-8.6%-12.9%-25.0%
Q3 2025+11.9%+2.6%-6.4%
Q1 2025+31.7%+21.4%+33.1%
Q4 2024-34.3%-43.7%-40.2%
Q3 2024-1.4%+6.3%+8.4%
Q2 2024-1.4%+5.1%+21.6%
Q1 2024-27.1%-27.5%-22.9%
Q4 2023+2.3%-4.2%-13.3%
Q3 2023+27.5%+29.5%+49.5%
Q2 2023-4.0%-6.2%-21.2%
Q1 2023+0.9%-3.7%+7.9%
Q4 2022+3.5%-1.6%-11.5%
Q3 2022-25.0%-29.7%-14.5%
Q2 2022-16.3%-18.6%-35.7%
Q1 2022-17.5%-31.3%-19.4%
Q4 2021+7.6%+13.6%+14.0%
Q3 2021-5.8%+0.2%-23.3%
Q2 2021
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro